시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 피부근염 치료 시장 보고서(2025년)
Dermatomyositis Treatment Global Market Report 2025
상품코드 : 1764299
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,546,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,462,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,378,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

피부근염 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 연평균 복합 성장률(CAGR) 6.9%를 나타내 12억 달러로 성장할 전망입니다. 예측기간 동안의 성장은 자가면역질환 연구에 대한 투자 증가, 새로운 생물학적 요법의 임상검사 증가, 표적 면역억제제의 채용 확대, 생명공학기업 간의 협력관계 확대, 개인화 치료 옵션에 대한 수요 증가로 이어집니다. 예측 기간에 예상되는 주요 동향으로는 표적 면역요법의 진전, mRNA 기반 치료법의 사용 확대, 신규 JAK 억제제의 개발, 인터페론 경로를 표적으로 하는 생물제제의 혁신, 맞춤형 치료 전략의 진전 등이 있습니다.

자가면역 질환의 유병률 증가는 향후 피부근염 치료 시장의 성장을 이끌 것으로 예측됩니다. 자가 면역 질환은 신체의 면역계가 실수로 자신의 건강한 세포와 조직을 공격하여 발생합니다. 이러한 자가면역 질환 증가는 진단 방법의 진보, 인지도의 향상, 환경 요인에 의해 촉진되어 발견률의 향상과 보고 사례 증가에 기여하고 있습니다. 피부근염의 치료는 유해한 면역 반응을 억제하고 환자의 QOL을 향상시키는 표적 치료를 제공함으로써 증가하는 유병률을 관리하는 데 도움이 됩니다. 예를 들어, 2024년 2월 미국 비영리 단체인 Autoimmune Institute는 자가면역 질환이 선진국 인구의 5-10%에 영향을 미친다고 보고했습니다. 그 결과 자가면역질환의 유병률 상승이 피부근염 치료 시장의 확대를 뒷받침하고 있습니다.

피부근염 치료 시장의 주요 기업은 면역계의 과잉 활성에 관여하는 특정 효소를 표적으로 함으로써 염증을 보다 잘 관리하는 JAK 억제제 등의 혁신적인 치료법의 개척에 주력하고 있습니다. 제약 회사 Pfizer는 2022년 6월, 피부근염 환자의 염증과 근력 저하를 억제하는 것을 목적으로 한 경구 JAK1과 TYK2 억제제 브레포시티닙을 발표했습니다. 경구제는 전통적인 주사 요법에 비해 보다 편리한 옵션을 제공하는 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

KTH
영문 목차

영문목차

Treatment of dermatomycosis involves antifungal therapies designed to eradicate fungal skin infections. This usually includes the use of topical antifungal creams or ointments like clotrimazole, miconazole, or terbinafine for mild to moderate cases. In more severe or stubborn infections, oral antifungal drugs such as fluconazole or itraconazole may be recommended.

The primary treatment methods for dermatomyositis consist of pharmacological therapies, immunosuppressants, corticosteroids, biologics, and physical therapy. Pharmacological treatments involve the use of medications to manage, relieve, or address symptoms and root causes of the disease. These medications can be administered orally, intravenously, or subcutaneously, with patient groups categorized by age and gender. Distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies, serving end users such as hospitals, home care providers, specialty clinics, and other users.

The dermatomyositis treatment market research report is one of a series of new reports from The Business Research Company that provides dermatomyositis treatment market statistics, including the dermatomyositis treatment industry global market size, regional shares, competitors with the dermatomyositis treatment market share, detailed dermatomyositis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatomyositis treatment industry. This dermatomyositis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dermatomyositis treatment market size has grown strongly in recent years. It will grow from $0.85 billion in 2024 to $0.91 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historical period is attributed to the rising prevalence of autoimmune diseases, increased awareness of rare inflammatory conditions, global growth in healthcare expenditure, higher diagnosis rates resulting from enhanced screening methods, and growing demand for effective alternatives to corticosteroids.

The dermatomyositis treatment market size is expected to see strong growth in the next few years. It will grow to $1.20 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The projected growth during the forecast period is driven by increasing investments in autoimmune disease research, a rise in clinical trials for new biologic therapies, greater adoption of targeted immunosuppressants, expanding collaborations among biotech companies, and growing demand for personalized treatment options. Key trends expected in the forecast period include progress in targeted immunotherapies, expanded use of mRNA-based therapies, development of new JAK inhibitors, innovations in biologics targeting interferon pathways, and advancements in personalized treatment strategies.

The rising prevalence of autoimmune diseases is anticipated to drive the growth of the dermatomyositis treatment market in the future. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells and tissues. This increase in autoimmune conditions is fueled by advancements in diagnostic methods, growing awareness, and environmental factors, which contribute to higher detection rates and more reported cases. Treatments for dermatomyositis help manage this growing prevalence by providing targeted therapies that suppress harmful immune responses and enhance patients' quality of life. For example, in February 2024, the Autoimmune Institute, a US-based nonprofit organization, reported that autoimmune diseases affect 5-10% of the population in industrialized countries. As a result, the rising prevalence of autoimmune diseases is propelling the expansion of the dermatomyositis treatment market.

Leading companies in the dermatomyositis treatment market are concentrating on developing innovative therapies, such as JAK inhibitors, to better manage inflammation by targeting specific enzymes involved in immune system overactivity. JAK inhibitors are drugs that block Janus kinase enzymes, helping to decrease the abnormal immune responses responsible for symptoms in autoimmune disorders. For example, in June 2022, Pfizer, a US-based pharmaceutical firm, introduced Brepocitinib, an oral JAK1 and TYK2 inhibitor aimed at reducing inflammation and muscle weakness in dermatomyositis patients. This oral form offers a more convenient option compared to traditional injectable therapies. Brepocitinib addresses the root causes of the disease and has demonstrated potential in enhancing patients' quality of life.

In April 2025, Syneron Bio, a biotechnology firm based in China, partnered with AstraZeneca to jointly develop and commercialize innovative oral peptide therapies targeting chronic and autoimmune diseases. This collaboration combines Syneron Bio's proprietary macrocyclic peptide technology with AstraZeneca's global expertise in drug development. AstraZeneca, headquartered in the UK, is a pharmaceutical company specializing in treatments for cancer, cardiovascular, and respiratory conditions.

Major players in the dermatomyositis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Fresenius SE & Co. KGaA, Bausch Health Companies Inc., Biotest AG, Galapagos NV, argenx SE, Roivant Sciences Ltd., Kymera Therapeutics Inc., Cabaletta Bio Inc., ImmunoForge Inc., NovelMed Therapeutics Inc., and Corbus Pharmaceuticals Holdings Inc.

North America was the largest region in the dermatomyositis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dermatomycosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dermatomycosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dermatomycosis treatment market consists of revenues earned by entities by providing services such as natural and herbal remedies, antifungal shampoos, and immune-modulating treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The dermatomycosis treatment market also includes sales of antifungal nail lacquers, oral suspensions, and pediatric formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dermatomyositis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dermatomyositis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for dermatomyositis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dermatomyositis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Dermatomyositis Treatment Market Characteristics

3. Dermatomyositis Treatment Market Trends And Strategies

4. Dermatomyositis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Dermatomyositis Treatment Growth Analysis And Strategic Analysis Framework

6. Dermatomyositis Treatment Market Segmentation

7. Dermatomyositis Treatment Market Regional And Country Analysis

8. Asia-Pacific Dermatomyositis Treatment Market

9. China Dermatomyositis Treatment Market

10. India Dermatomyositis Treatment Market

11. Japan Dermatomyositis Treatment Market

12. Australia Dermatomyositis Treatment Market

13. Indonesia Dermatomyositis Treatment Market

14. South Korea Dermatomyositis Treatment Market

15. Western Europe Dermatomyositis Treatment Market

16. UK Dermatomyositis Treatment Market

17. Germany Dermatomyositis Treatment Market

18. France Dermatomyositis Treatment Market

19. Italy Dermatomyositis Treatment Market

20. Spain Dermatomyositis Treatment Market

21. Eastern Europe Dermatomyositis Treatment Market

22. Russia Dermatomyositis Treatment Market

23. North America Dermatomyositis Treatment Market

24. USA Dermatomyositis Treatment Market

25. Canada Dermatomyositis Treatment Market

26. South America Dermatomyositis Treatment Market

27. Brazil Dermatomyositis Treatment Market

28. Middle East Dermatomyositis Treatment Market

29. Africa Dermatomyositis Treatment Market

30. Dermatomyositis Treatment Market Competitive Landscape And Company Profiles

31. Dermatomyositis Treatment Market Other Major And Innovative Companies

32. Global Dermatomyositis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dermatomyositis Treatment Market

34. Recent Developments In The Dermatomyositis Treatment Market

35. Dermatomyositis Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기